<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160272</url>
  </required_header>
  <id_info>
    <org_study_id>GAP-325</org_study_id>
    <nct_id>NCT05160272</nct_id>
  </id_info>
  <brief_title>Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes</brief_title>
  <official_title>Effects of GABAA Receptor Modulation by AP-325 on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Deutsche Diabetes Forschungsgesellschaft e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>komIT - Center of Competence for Innovative Diabetes Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this single-center, prospective, randomized, double-blind, placebo-controlled,&#xD;
      2-arm parallel-group interventional study is to investigate the effect of 4-week treatment&#xD;
      with AP-325 on C-peptide release as measure of insulin secretion compared to placebo in type&#xD;
      2 diabetes (T2D) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating C-peptide by iAUC of C-peptide during an IVGTT</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in circulating C-peptide levels from baseline to end of intervention measured by iAUC of C-peptide during an IVGTT until 60th minute (second phase) with AP-325 compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal insulin level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in basal insulin level from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in C-peptide level from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in glucose level from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of circulating insulin (overall)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in iAUC of circulating insulin during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of C-peptide level (overall)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in C-peptide level during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of glucose level (overall)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in iAUC of glucose level during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of circulating insulin (AIR) (first 10 min)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in iAUC of circulating insulin (AIR) during an IVGTT in the first 10 minutes from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of C-peptide (first 10 min)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in iAUC of C-peptide during an IVGTT in the first 10 minutes from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iAUC of glucose (first 10 min)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in iAUC of glucose during an IVGTT in the first 10 minutes from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disposition index (DI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in the disposition index (DI) through Minimal Model during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak insulin response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in peak insulin response during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion rate (ISR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in insulin secretion rate (ISR) during an IVGTT from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in 1.5-Anhydroglucitol glucose from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine levels II</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in fructosamine level from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fructosamine levels III</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in fasting blood glucose from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AP-325</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in Plasma concentrations of AP-325 at 1 hour post-dose on Days 1 and 28; pre-dose on Days 4 and 28. Accumulation of Ctrough from Day 4 to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough-ss (Day 28) and the change from baseline to Day 28</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in relationship between Ctrough-ss (Day 28) and the change from baseline to Day 28 in primary and secondary endpoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>AP-325 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP-325, film-coated tablet, 50mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching AP-325 film-coated tablet, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP-325</intervention_name>
    <description>Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.</description>
    <arm_group_label>AP-325 Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching AP-325</intervention_name>
    <description>Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T2D&#xD;
&#xD;
          -  Age between 25 and 75 years&#xD;
&#xD;
          -  HbA1c ≥6.5 and ≤9.5 %&#xD;
&#xD;
          -  BMI ≤ 45 kg/m2&#xD;
&#xD;
          -  Treatment-naive or stable antihyperglycemic therapy with metformin,&#xD;
             α-glucosidase-inhibitor and/or SGLT2 inhibitor&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute infections (hsCRP &gt; 5mg/dl, body temperature &gt;37.5°C)&#xD;
&#xD;
          -  Insulin therapy or treatment with sulfonylureas, glinides, GLP-1 receptor agonists,&#xD;
             thiazolidinediones; current treatment with DPP-4 inhibitors or during the 4 weeks&#xD;
             prior to baseline examination&#xD;
&#xD;
          -  Uncontrolled hyperglycemia, e.g. fasting blood glucose &gt;240 mg/dl&#xD;
&#xD;
          -  Heart rate &lt;50 or &gt;100 beats per minute; systolic blood pressure &lt;100 or &gt;160 mmHg;&#xD;
             diastolic blood pressure &lt;50 or &gt;100 mmHg; uncontrolled hypertension&#xD;
&#xD;
          -  Creatinine clearance &lt;60 ml/min (eGFR by MDRD formula)&#xD;
&#xD;
          -  Severe chronic illnesses, such as congestive heart failure (NYHA III/IV), liver&#xD;
             insufficiency (Child-Pugh Class B/C), history of acute coronary syndrome, stroke&#xD;
&#xD;
          -  Anemia (Hb &lt;12 g/l for men, Hb &lt;11 g/l for women)&#xD;
&#xD;
          -  Participation in another intervention study within 2 months before the examination&#xD;
&#xD;
          -  Hypersensitivity against AP-325, placebo or other ingredients of IMP&#xD;
&#xD;
          -  Immunocompromising diseases&#xD;
&#xD;
          -  Immunomodulatory drugs (e.g. oral cortisone preparations, biologicals)&#xD;
&#xD;
          -  Thyroid diseases with an unstable metabolic state (change in L-thyroxine dose within&#xD;
             the past 6 weeks, TSH and fT4 outside the normal range)&#xD;
&#xD;
          -  Planned pregnancy, pregnant or lactating women, positive pregnancy test, and woman of&#xD;
             childbearing potential not using two adequate methods of contraception, including a&#xD;
             barrier method and a highly efficacious non-barrier method&#xD;
&#xD;
          -  Past (≤ 5 years) or current history of psychiatric disorders, including psychiatric&#xD;
             depression&#xD;
&#xD;
          -  HIV, hepatitis B or C disease&#xD;
&#xD;
          -  Previous / current alcohol and / or drug abuse&#xD;
&#xD;
          -  Malignant cancer&#xD;
&#xD;
          -  BIA and MR-incompatible metal or magnetic implants, devices or objects inside of or on&#xD;
             the body, claustrophobia&#xD;
&#xD;
          -  Treatment with the following drug groups or agents:&#xD;
&#xD;
        Anticoagulant drugs (exception: acetylsalicylic acid 100 mg/day), dihydropyridines (e.g.&#xD;
        nifedipine, amlodipine), azilsartan, losartan and irbesartan, celecoxib; if applicable,&#xD;
        other drugs that are predominantly metabolized by CYP2C9&#xD;
&#xD;
          -  Inhibitors or inducers of CYP2C9, CYP3A4, such as amiodarone, verapamil, rifampicin&#xD;
&#xD;
          -  Poor CYP2C9 metabolizer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Diabetes-Zentrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Kahl, MD</last_name>
    <phone>+49 211 3382 0</phone>
    <email>sabine.kahl@ddz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Pützer, MD</last_name>
    <phone>+49 211 3382 0</phone>
    <email>jennifer.puetzer-furmanczak@ddz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Duesseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabine Kahl</last_name>
      <phone>+492113382 698</phone>
      <email>sabine.kahl@ddz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>GABAA receptor</keyword>
  <keyword>β-cell function</keyword>
  <keyword>glycemic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

